At Least Three Ring Hetero Atoms In The Bicyclo Ring System Patents (Class 548/153)
  • Patent number: 8003675
    Abstract: A 3,4-dihalogenoisothiazole derivative represented by the general formula [I] (wherein R1 is a halogen atom; A is an oxygen atom or a sulfur atom; and R is a C1-C6 alkyl group, a C2-C5 alkenyl group, a C2-C5 alkynyl group, a C3-C6 cycloalkyl group, a phenyl group or a 5- to 10-membered heterocyclic group containing at least one of oxygen atom, sulfur atom and nitrogen atom), or a salt thereof.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: August 23, 2011
    Assignees: Kumiai Chemical Industry Co., Ltd., Ihara Chemical Industry Co., Ltd.
    Inventors: Toshihiro Nagata, Atsushi Kogure, Isao Kaneko, Norihisa Yonekura, Ryo Hanai
  • Publication number: 20110195986
    Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1, R4, R5, R3, R3a, W, D, R2a, R2b and R2c are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression, anxiety or intestinal inflammation, by administration of a therapeutically effective dose of a compound according to Formula I.
    Type: Application
    Filed: October 8, 2009
    Publication date: August 11, 2011
    Inventors: Guohua Zhao, William N. Washburn, James J. Mignone
  • Publication number: 20110177653
    Abstract: Provided are an organic semiconductor compound using thiazole, and an organic thin film transistor having an organic semiconductor layer formed of the organic semiconductor compound using thiazole. The novel organic semiconductor compound including thiazole has liquid crystallinity and excellent thermal stability, and thus is provided to form an organic semiconductor layer in the organic thin film transistor. To this end, a silicon oxide layer is formed on a silicon substrate, and an organic semiconductor layer including thiazole is formed on the silicon oxide layer. In addition, source and drain electrodes are formed on both edge portions of the organic semiconductor layer. The organic thin film transistor using the organic semiconductor layer has an improved on/off ratio and excellent thermal stability. Also, a solution process can be applied in its manufacture.
    Type: Application
    Filed: January 24, 2011
    Publication date: July 21, 2011
    Applicant: Gwangju Institute of Science and Technology
    Inventors: Dong-Yu Kim, Bogyu Lim, Kang-Jun Baeg, Hyung-Gu Jeong, Seung-Hwan Oh, Hong-Ju Park
  • Publication number: 20110150827
    Abstract: Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
    Type: Application
    Filed: December 17, 2010
    Publication date: June 23, 2011
    Applicant: Idenix Pharmaceuticals, Inc.
    Inventors: Cyril B. Dousson, David Dukhan, Christophe Claude Parsy, Claire Pierra, Francois-Rene Alexandre, Guillaume Brandt, Daniel Da Costa, Houcine Rahali, Jean-Laurent Paparin, Michel Derock, Thierry Convard, Dominique Surleraux
  • Publication number: 20110152251
    Abstract: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-?B activation to treat viral infections and inflammatory conditions.
    Type: Application
    Filed: November 17, 2010
    Publication date: June 23, 2011
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Shenghua Zhou
  • Patent number: 7935828
    Abstract: The present invention is directed to the provision of a novel liquid crystalline organic semiconductor material that is highly stable under an film forming environment and, at the same time, can easily form a film, for example, by coating.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: May 3, 2011
    Assignee: Dai Nippon Printing Co., Ltd.
    Inventors: Ken Tomino, Shigeru Sugawara, Hiroki Maeda, Masanao Matsuoka
  • Publication number: 20110086999
    Abstract: The invention provides a thiazolothiazole compound represented by the following Formula (I). In Formula (I), Ar1 represents a substituted or unsubstituted aromatic group; R1 represents a hydrogen atom, an alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group; and n represents an integer of 0 or 1. The invention further provides a thiazolothiazole polymer having the thiazolothiazole compound as a polymerization unit thereof.
    Type: Application
    Filed: May 14, 2010
    Publication date: April 14, 2011
    Applicant: FUJI XEROX CO., LTD.
    Inventors: Hidekazu Hirose, Takeshi Agata, Katsuhiro Sato, Kazuaki Sato, Yoshihiro Ohba
  • Patent number: 7906649
    Abstract: The present invention is directed to novel substituted aminocyclohexanes which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: March 15, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tesfaye Biftu, Danqing Feng, Xiaoxia Qian, Ann E. Weber, Jason Cox
  • Patent number: 7906553
    Abstract: Described herein are compounds of Formula (I) having the structure: where A, J, R1, R4, Z and X are described herein; and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: March 15, 2011
    Assignee: CalciMedica, Inc.
    Inventors: Gonul Velicelebi, Kenneth A. Stauderman, Jeffrey P. Whitten, Yazhong Pei, Jianguo Cao, Zhijun Wang, Evan Rogers, Brian Dyck, Jonathan Grey
  • Patent number: 7829658
    Abstract: The invention relates to novel mono-, oligo- and polymeric compounds comprising thienothiazole groups, to their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices, and to optical, electro-optical or electronic devices comprising the novel compounds.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: November 9, 2010
    Assignee: Merck Patent Gesellschaft
    Inventors: Warren Duffy, Martin Heeney, Iain McCulloch
  • Publication number: 20100276672
    Abstract: An organic electroluminescent device includes: a pair of electrodes including a positive electrode and a negative electrode, at least one of the electrodes being transparent or semi-transparent; and an organic compound layer including one or more layers interposed between the pair of electrodes, at least one layer included in the organic compound layer containing one or more compounds represented by the following formula (I): in formula (I), R1s each independently representing a linear alkyl, linear alkoxy, branched alkyl, or branched alkoxy group having from 3 to 20 carbon atoms; and R2s each independently representing a hydrogen atom, a linear alkyl group having from 1 to 20 carbon atoms, a linear alkoxy group having from 1 to 20 carbon atoms, a branched alkyl group having from 3 to 20 carbon atoms, or a branched alkoxy group having from 3 to 20 carbon atoms.
    Type: Application
    Filed: November 20, 2009
    Publication date: November 4, 2010
    Applicant: FUJI XEROX CO., LTD.
    Inventors: Akira IMAI, Koji HORIBA, Hidekazu HIROSE, Takeshi AGATA, Katsuhiro SATO
  • Patent number: 7812172
    Abstract: A thiazolothiazole derivative is represented by the following Formula (I). In Formula (I), each R1 independently represents a straight chain alkyl group having 3 to 20 carbon atoms, a straight chain alkoxy group having 3 to 20 carbon atoms, a branched alkyl group having 3 to 20 carbon atoms, or a branched alkoxy group having 3 to 20 carbon atoms; and each R2 independently represents a hydrogen atom, a straight chain alkyl group having 1 to 20 carbon atoms, a straight chain alkoxy group having 1 to 20 carbon atoms, a branched alkyl group having 3 to 20 carbon atoms, or a branched alkoxy group having 3 to 20 carbon atoms.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: October 12, 2010
    Assignee: Fuji Xerox Co., Ltd.
    Inventors: Koji Horiba, Hidekazu Hirose, Akira Imai, Katsuhiro Sato, Takeshi Agata
  • Publication number: 20100236631
    Abstract: The present invention relates to novel thiazolothiazole derivatives and an organic electronic device such as an organic light emitting device, an organic transistor, and an organic solar cell using the same. In the compound of the invention, various substituents are introduced to the core structure, so as to satisfy the requirements such as suitable energy levels, and electrochemical and thermal stability, and also have amorphous or crystalline property depending on the kind of the substituents, so as to satisfy the characteristics individually required for each of the devices. Further, an organic semiconductor of p-type or n-type can be fabricated by introducing various substituents to the core structure having a property of n-type. Therefore, the compound of the present invention can provide a device having higher stability.
    Type: Application
    Filed: June 15, 2007
    Publication date: September 23, 2010
    Applicant: LG CHEM, LTD.
    Inventors: Roman Kiselev, Seok-Hee Yoon, Hyeon Choi, Jae-Min Lee
  • Patent number: 7795257
    Abstract: The present invention provides compounds of the formula which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for the prevention and the treatment of impaired glucose tolerance, type 2 diabetes and obesity.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: September 14, 2010
    Assignee: Novartis AG
    Inventor: Gregory Raymond Bebernitz
  • Publication number: 20100204472
    Abstract: This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.
    Type: Application
    Filed: April 13, 2010
    Publication date: August 12, 2010
    Inventors: Louis-David Cantin, Soongyu Choi, Roger B. Clark, Martin F. Hentemann, Xin Ma, Joachim Rudolph, Sidney X. Liang, Christiana Akuche, Rico C. Lavoie, Libing Chen, Dyuti Majumdar, Philip L. Wickens
  • Patent number: 7772261
    Abstract: The disclosure relates to a compound of formula (I): in which: R1, R2, R3 and R4 are as described in the specification, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these compounds and to certain intermediate products.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: August 10, 2010
    Assignee: sanofi-aventis
    Inventors: Gilles Doerflinger, Jean-Christophe Carry
  • Patent number: 7767824
    Abstract: Heterocyclic compound represented by the formula I wherein represents or the like; R1 represents hydrogen atom, C1-C6 alkyl or benzyloxy; R2 represents methyl or nil; R3 represents hydrogen atom, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl or —CH2R5 [wherein R5 represents phenyl (which may be substituted with C1-C6 alkyl, halogen atom or cyano)] or thienyl; R4 represents C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl or —CH2R6 [wherein R6 represents phenyl (which may be substituted with C1-C6alkyl, halogen atom or cyano), naphtyl or thienyl]; or R3 is coupled with R4.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: August 3, 2010
    Assignee: Zenyaku Kogyo Kabushiki Kaisha
    Inventors: Seiichiro Kawashima, Toshiyuki Matsuno, Naoki Fukuda, Kenichi Saitoh, Yoshimasa Yamaguchi, Masaya Higashi
  • Publication number: 20100179190
    Abstract: The present invention provides novel bicyclic pyrazolo kinase modulators and methods of using the novel bicyclic pyrazolo kinase modulators to treat diseases mediated by kinase activity.
    Type: Application
    Filed: November 14, 2008
    Publication date: July 15, 2010
    Applicant: SGX PHARMACEUTICALS, INC.
    Inventors: Pierre-Yves Bounaud, Andrew Vaino
  • Patent number: 7750034
    Abstract: The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: January 19, 2007
    Date of Patent: July 6, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tesfaye Biftu, Jason Cox, Danqing Feng, Anthony Mastracchio, Xiaoxia Qian, Ann E. Weber
  • Patent number: 7700616
    Abstract: The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: April 20, 2010
    Assignee: Molecular Neuroimaging, LLC.
    Inventors: Gilles D. Tamagnan, David Alagille, Herve Da Costa
  • Patent number: 7652020
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-? or combinations thereof.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: January 26, 2010
    Assignee: Schering Corporation
    Inventors: Zhuyan Guo, Peter Orth, Zhaoning Zhu, Robert D. Mazzola, Tin-Yau Chan, Henry A. Vaccaro, Brian McKittrick, Joseph A. Kozlowski, Brian J. Lavey, Guowei Zhou, Sunil Paliwal, Shing-Chun Wong, Neng-Yang Shih, Pauline C. Ting, Kristin E. Rosner, Gerald W. Shipps, Jr., M. Arshad Siddiqui, David B. Belanger, Chaoyang Dai, Dansu Li, Vinay M. Girijavallabhan, Janeta Popovici-Muller, Wensheng Yu, Lianyun Zhao
  • Publication number: 20100016386
    Abstract: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc
    Type: Application
    Filed: August 31, 2007
    Publication date: January 21, 2010
    Inventors: David Vocadlo, Ernest McFachern, Keith Stubbs, Tong-Shuang Li, Garrett Whitworth, Julia Heinonen, Matthew Macauley
  • Patent number: 7638513
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-? or combinations thereof.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: December 29, 2009
    Assignee: Schering Corporation
    Inventors: M. Arshad Siddiqui, Umar Faruk Mansoor, Panduranga A. Reddy, Vincent S. Madison
  • Patent number: 7625923
    Abstract: The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R1, R2, R5, X, Y and n are defined herein.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: December 1, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alexandra Nirschl, James C. Sutton, Lawrence Hamann, Tammy Wang, Yan Zou, Chongqing Sun
  • Publication number: 20090270467
    Abstract: The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Application
    Filed: January 19, 2007
    Publication date: October 29, 2009
    Applicant: MERCK & CO., INC.
    Inventors: Tesfaye Biftu, Jason Cox, Danqing Feng, Anthony Mastracchio, Xiaoxia Qian, Ann E. Weber
  • Patent number: 7563901
    Abstract: The present invention relates to compounds represented by formula (1) and a process for producing the same. The use of these compounds can realize the production of carbapenem derivatives having potent antimicrobial activity and a wide antimicrobial spectrum in a safe and cost-effective manner.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: July 21, 2009
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Toshiro Sasaki, Takashi Ando, Yasuo Yamamoto, Takahiro Imai, Dai Kubota, Katsuhiko Noguchi, Nobuyuki Hori, Eiki Shitara, Kunio Atsumi, Shohei Yasuda
  • Publication number: 20090176779
    Abstract: The disclosure relates to a compound of formula (I): in which: R1, R2, R3 and R4 are as described in the specification, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these compounds and to certain intermediate products.
    Type: Application
    Filed: January 21, 2009
    Publication date: July 9, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Gilles DOERFLINGER, Jean-Christophe CARRY
  • Publication number: 20090152538
    Abstract: Provided are an organic semiconductor compound using thiazole, and an organic thin film transistor having an organic semiconductor layer formed of the organic semiconductor compound using thiazole. The novel organic semiconductor compound including thiazole has liquid crystallinity and excellent thermal stability, and thus is provided to form an organic semiconductor layer in the organic thin film transistor. To this end, a silicon oxide layer is formed on a silicon substrate, and an organic semiconductor layer including thiazole is formed on the silicon oxide layer. In addition, source and drain electrodes are formed on both edge portions of the organic semiconductor layer. The organic thin film transistor using the organic semiconductor layer has an improved on/off ratio and excellent thermal stability. Also, a solution process can be applied in its manufacture.
    Type: Application
    Filed: December 1, 2008
    Publication date: June 18, 2009
    Applicant: Gwangju Institute of Science and Technology
    Inventors: Dong-Yu Kim, Bogyu Lim, Kang-Jun Baeg, Hyung-Gu Jeong, Seung-Hwan Oh, Hong-Ju Park
  • Publication number: 20090156827
    Abstract: An object of the present invention is to provide a material for high-brightness, high-efficiency, longer-life organic EL elements and an organic EL element produced by using the same. Provided is a material for organic EL elements, comprising a compound represented by the following General Formula (1): wherein, R1 and R2 each independently represent a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heterocyclic group.
    Type: Application
    Filed: March 19, 2007
    Publication date: June 18, 2009
    Applicant: TOYO INK MFG. CO., LTD.
    Inventor: Yoshiyuki Takata
  • Patent number: 7473783
    Abstract: The present invention provides novel bicyclic pyrazolo kinase modulators and methods of using the novel bicyclic pyrazolo kinase modulators to treat diseases mediated by kinase activity.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: January 6, 2009
    Assignee: SGX Pharmaceuticals, Inc.
    Inventors: Pierre-Yves Bounaud, Andrew Vaino
  • Publication number: 20080287510
    Abstract: The present application relates to thiazolylidene containing compounds of formula (I) wherein R1, R2, R3, and R4 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    Type: Application
    Filed: May 15, 2008
    Publication date: November 20, 2008
    Applicant: Abbott Laboratories
    Inventors: William A. Carroll, Michael J. Dart, Arturo Perez-Medrano, Jennifer M. Frost, Sridhar Peddi
  • Patent number: 7419993
    Abstract: The invention relates to triazolo-thiazole analogues of epothilone A and epothilone B.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: September 2, 2008
    Assignee: Helmholtz Center of Infection Research GmbH
    Inventors: Gerhard Hoefle, Nicole Glaser
  • Publication number: 20080200634
    Abstract: The invention relates to novel mono-, oligo- and polymeric compounds comprising thienothiazole groups, to their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices, and to optical, electro-optical or electronic devices comprising the novel compounds.
    Type: Application
    Filed: May 11, 2006
    Publication date: August 21, 2008
    Applicant: MERCK PATENT GESELLSCHAFT
    Inventors: Warren Duffy, Martin Heeney, Iain McCulloch
  • Patent number: 7393867
    Abstract: The present invention discloses and claims compounds of formula (I) and formula (II), as inhibitors of human casein kinase I? and methods for using said compounds for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) or formula (II) and a method for the preparation of compounds of formula (I) or formula (II) are also disclosed and claimed.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: July 1, 2008
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: David Marc Fink, Yulin Chiang, Nicola Dawn Collar
  • Patent number: 7300949
    Abstract: This invention concerns novel thiazolopyrazole compounds and compositions comprising them. Methods of using these compounds for the treatment, prevention and management of various diseases and disorders are also encompassed by the invention.
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: November 27, 2007
    Assignee: Lexicon Pharmaceuticals, Inc.
    Inventors: Joseph Barbosa, Cynthia A. Fink, Spencer D. Kimball, Hartmuth Kolb, Zhi-Cai Shi, Ashok R. Tunoori
  • Patent number: 7253154
    Abstract: The invention relates to compounds of the following formula (I) or their salts: in which R1 represents OR4 or others, in which R4 is an alkyl group having 1-8 carbon atoms which may have a substituent or the like; R2 is halogen, nitro, cyano, carboxyl, or the like; R3 is hydrogen, halogen, hydroxyl, amino, carboxyl, or the like; X is NR11, oxygen, or sulfur, in which R11 is hydrogen, or an alkyl group having 1-8 carbon atom which may have a substituent; and each of Y and Z is CR12 or nitrogen, in which R12 has the same meaning as R3 above, and a xanthine oxidase inhibitor containing the compound as an active ingredient.
    Type: Grant
    Filed: November 14, 2002
    Date of Patent: August 7, 2007
    Assignee: Nippon Chemiphar Co., Ltd.
    Inventors: Shinichi Yoshida, Atsushi Tendo, Kunio Kobayashi, Nobutaka Mochiduki, Tomio Yamakawa, Yoriko Shinohara
  • Patent number: 7153878
    Abstract: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I. (Formula I); wherein: (a) R5 is selected from the group consisting of (C1–C6)alkyl, (C1–C6)alkenyl, aryl (C0–C4)alkyl, aryloxy(C0–C4)alkyl, arylthio(C0–C4)alkyl, and further wherein when R5 is alkyl, R5 can optionally combine with W to form a 6 membered cycloheteroalkyl ring that is fused with the oxazole or thiazole ring to which the R5 group is attached; (b) R9 is selected from the group consisting of C1–C5alkyl, C1–C5alkenyl, and arylC0–C3alkyl.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: December 26, 2006
    Assignee: Eli Lilly and Company
    Inventors: Scott Eugene Conner, James Allen Knobelsdorf, Nathan Bryan Mantlo, Jeffrey Michael Schkeryantz, Quanrong Shen, Alan M Warshawsky, Guoxin Zhu
  • Patent number: 7018997
    Abstract: The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof. wherein one of A and B denotes hydrogen and the other an optionally substituted fused tricyclic heteroaryl group; and X is S.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: March 28, 2006
    Assignee: Wyeth
    Inventors: Aranapakam Mudumbai Venkatesan, Tarek Suhayl Mansour, Takao Abe, Ado Mihira, Atul Agarwal, Hideki Ushirogochi, Yansong Gu, Satoshi Tamai, Fuk-Wah Sum
  • Patent number: 6893650
    Abstract: The invention provides fungicidal compounds of formula (I) and salts thereof wherein: R1 is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted, or hydrogen; R2 and R3, which may be the same or different, are any group defined for R1; cyano; acyl; —ORa or —SRa, where Ra is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted; or R2 and R3, or R2 and R1, together with their interconnecting atoms may form a ring, which may be substituted; R4 is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted; hydroxy; mercapto; azido; nitro; halogen; cyano; acyl; optionally substituted amino; cyanato; thiocyanato; —SF5; —ORa; —SRa or —Si(Ra)3; m is 0 to 3; when present R5, which may be the same or different to any other R5, is any group defined for R4; R6 is optionally substituted carbo- or heterocylclyl; and A is a defined linking group, or —A—R6 and R5 together with benzene ring M form an optionally substituted fused ri
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: May 17, 2005
    Assignee: Bayer Cropscience GmbH
    Inventors: Mark David Charles, Wilfried Franke, David Eric Green, Thomas Lawley Hough, Dale Robert Mitchell, Donald James Simpson, John Frederick Atherall
  • Patent number: 6730793
    Abstract: Provided are chromophores of the formula Q—(—L—Z)x, wherein x is 2 or 3, wherein Q is selected from the group consisting of wherein L is wherein R is an alkyl group having 1 to 20 carbon atoms, and wherein Z is selected from the group consisting of
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: May 4, 2004
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Ramamurthi Kannan, Loon-Seng Tan, Bruce A. Reinhardt, Richard A. Vaia
  • Patent number: 6727246
    Abstract: The present invention provides compounds of formula I and the use thereof for the treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: April 27, 2004
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Schuyler A. Antane, Ping Zhou, Yanfang Li
  • Publication number: 20040077646
    Abstract: Compounds of the formula (I) 1
    Type: Application
    Filed: June 2, 2003
    Publication date: April 22, 2004
    Inventors: Joe Timothy Bamberg, Tobias Gabriel, Nancy Elisabeth Krauss, Taraneh Mirzadegan, Wylie Solang Palmer, David Bernard Smith
  • Publication number: 20040053981
    Abstract: Abstract Asymmetric derivatives of furamidines with one of the phenyl rings of furamidine replaced with a benzimidazole have been found by quantitative footprinting analyses to bind GC containing sites on DNA more strongly than to pure AT sequences. These compounds have been shown to bind in the minor groove at specific GC containing sequences of DNA in a highly cooperative manner as a stacked dimer. Compounds of the present invention find use in selectively binding mixed sequence DNA, and may also be used in methods of regulating gene expression, methods of treating opportunistic infections and cancer, as well as in methods of detecting certain sequences of DNA.
    Type: Application
    Filed: September 2, 2003
    Publication date: March 18, 2004
    Inventors: W. David Wilson, David W. Boykin, Richard R. Tidwell
  • Patent number: 6706724
    Abstract: The invention describes novel substituted aryl compounds that are cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent, such as, steroids, nonsterodal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H2 antagonists, antineoplastic agents, antiplatelet agents, thrombin inhibitors, thromboxane inhibitors, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pyl
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: March 16, 2004
    Assignee: NitroMed, Inc.
    Inventors: Subhash P. Khanapure, David S. Garvey, Richard A. Earl, Maiko Ezawa, Xinqin Fang, Ricky D. Gaston
  • Publication number: 20040019219
    Abstract: The present invention relates to N-alkylated thiazolium salts, to a process for their preparation and also to their use as condensation and dehydrating agents.
    Type: Application
    Filed: June 10, 2003
    Publication date: January 29, 2004
    Inventors: Ralf Wischnat, Joachim Rudolph
  • Publication number: 20030195361
    Abstract: This invention relates to compounds of Formula I 1
    Type: Application
    Filed: February 14, 2003
    Publication date: October 16, 2003
    Applicant: Pfizer Inc.
    Inventor: Daisy Joe Du Bois
  • Patent number: 6608070
    Abstract: This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein Z is OH, C1-6 alkoxy, —NR2R3 or heterocycle; Q is selected from the following: (a) an optionally substituted phenyl, (b) an optionally substituted 6-membered monocyclic aromatic group containing one, two, three or four nitrogen atom(s), (c) an optionally substituted 5-membered monocyclic aromatic group containing one heteroatom selected from O, S and N and optionally containing one, two or three nitrogen atom(s) in addition to said heteroatom, (d) an optionally substituted C3-7 cycloalkyl and (e) an optionally substituted benzo-fuzed heterocycle; R1 is hydrogen, C1-4 alkyl or halo; R2 and R3 are independently hydrogen, OH, C1-4 alkoxy, C1-4 alkyl or C1-4 alkyl substituted with halo, OH, C1-4 alkoxy or CN; X is independently selected from H, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, OH, C1-4 alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, NO2, NH2, di-(C1-4 al
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: August 19, 2003
    Inventors: Kazunari Nakao, Rodney William Stevens, Kiyoshi Kawamura, Chikara Uchida, Hiroki Koike, Stephane Caron
  • Patent number: 6576780
    Abstract: The current invention discloses hydroxyamidino derivatives useful as nitric oxide synthase inhibitors.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: June 10, 2003
    Assignee: GD Searle & Company
    Inventors: Rolando E. Gapud, Timothy J. Hagen, E. Ann Hallinan, Donald W. Hansen, Jr., Barnett S. Pitzele, Suzanne S. Metz, R. Keith Webber, Foe S. Tjoeng, Robert E. Manning, Mihaly V. Toth
  • Patent number: 6566363
    Abstract: Pyrazole-thiazole compounds that modulate and/or inhibit the activity of cyclin-dependent kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating cyclin-dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: May 20, 2003
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Wesley Kwan Mung Chong, Rohit Kumar Duvadie
  • Publication number: 20030091861
    Abstract: Disclosed is a material for a light emitting device excellent in color purity, good in light emitting characteristics and excellent in stability, which consists of a compound represented by the following general formula (I):
    Type: Application
    Filed: August 21, 2002
    Publication date: May 15, 2003
    Applicant: FUJI PHOTO FILM CO., LTD.
    Inventors: Hisashi Okada, Toshihiro Ise